ONO-4538 Phase I Study in Patients With Solid Tumor
The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.
Advanced Solid Tumors|Recurrent Solid Tumors
DRUG: ONO-4538
Safety outcome: The number of subjects with overall adverse events, Approximately 6 months|Safety outcome: The number of deaths, Approximately 6 months|PK outcome: Cmax of ONO-4538, Approximately 10 months|Efficacy outcome: Response rate, Approximately 6 months|Efficacy outcome: Progression free survival, Approximately 6 months
The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.